Costantino Luca, Barlocco Daniela
University of Modena e Reggio Emilia, Dipartimento di Scienze Farmaceutiche, Via Campi 183, 41100 Modena, Italy.
Curr Med Chem. 2006;13(1):65-85.
Among the strategies that can lead to the discovery of new drugs, the identification and use of privileged structures, molecular fragments that are able to interact with more than one target, gained particular attention, in an attempt to find new drugs in a shorter time with respect to other strategies. These structures, that have been identified mainly by empirical observations, can target only a given protein family, or can be able to interact with more, unrelated targets. This review deals with structures not covered in recent papers on this topic, and emphasizes the importance of understanding the structure-target relationships, that confer the privileged status.
在可能促成新药发现的策略中，特权结构（即能够与不止一个靶点相互作用的分子片段）的识别与应用受到了特别关注，旨在相较于其他策略在更短时间内找到新药。这些结构主要通过经验观察得以识别，它们可能仅针对特定的蛋白质家族，也可能能够与更多不相关的靶点相互作用。本综述探讨了近期关于该主题的论文中未涉及的结构，并强调了理解赋予特权地位的结构-靶点关系的重要性。
